Front. Immunol.

Frontiers in Immunology

Front. Immunol.

1664-3224

Frontiers Media S.A.

10.3389/fimmu.2022.1097810

Immunology

Erratum

Erratum: Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality

Frontiers Production Office ^*

Frontiers Media SA, Lausanne, Switzerland

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Frontiers Production Office, production.office@frontiersin.org

This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology

13 12 2022

2022

1097810

14 11 2022 14 11 2022

2022

Frontiers Production Office

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

An Erratum on: Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality. By Schneider F, Le Borgne P, Herbrecht J-E, Danion F, Solis M, Hellé S, Betscha C, Clere-Jehl R, Lefebvre F, Castelain V, Goumon Y and Metz-Boutigue M-H (2022) Front. Immunol. 13:985472. doi: 10.3389/fimmu.2022.985472

Innate immunity COVID Catestatin Chromogranin A hypoxia critically ill nosocomial disease

Due to a production error, there was a mistake in Figure 1 as published. The wrong figure was inserted as Figure 1 . The corrected Figure 1 appears below. The publisher apologizes for this mistake.

Figure 1

Flow chart of the study. Study participants (n=100) were screened for participation during the first surge of the disease (March to May 2020) among 547 patients admitted for COVID either to the emergency department or to the ICU. Informed consent for participation was obtained in 49 COVID+ ICU+ patients, and in 24 COVID+ICU- patients, which were then admitted to the infectious disease department. In parallel, 11 participants were recruited in our staff (as healthy controls, COVID-ICU-), and so were 16 COVID-ICU+ patients that were admitted for non-COVID multiple organ failure requiring mechanical ventilation support.